VTR(SZ:300381)2018-04-27 16:00Financial Performance - Total revenue for Q1 2018 was CNY 335,864,495.95, representing a 9.51% increase compared to CNY 306,687,565.40 in the same period last year[7] - Net profit attributable to shareholders was CNY 11,537,529.35, up 4.58% from CNY 11,031,967.88 year-on-year[7] - Basic and diluted earnings per share increased to CNY 0.0284, reflecting a growth of 4.80% from CNY 0.0271[7] - The company's total profit for Q1 2018 was CNY 26,598,858.75, representing a 56.67% increase from CNY 16,982,136.73 in the previous year[44] - The net profit for Q1 2018 reached CNY 20,776,953.57, up 43.83% from CNY 14,466,212.61 in Q1 2017[44] - The gross profit margin improved to 51.8% in Q1 2018, compared to 46.5% in Q1 2017[46] Cash Flow - Net cash flow from operating activities was negative CNY 4,824,356.70, a decline of 79.76% compared to positive CNY 14,225,666.87 in the previous year[7] - The company reported a cash inflow from operating activities of CNY 380,309,920.47 in Q1 2018, compared to CNY 223,426,902.85 in the previous year[49] - The net cash flow from operating activities was -4,824,356.70 CNY, compared to -23,840,333.13 CNY in the previous period, indicating an improvement[50] - Total cash inflow from financing activities was 305,285,000.00 CNY, up from 213,025,936.34 CNY year-over-year[51] - The net cash flow from investing activities was -83,378,661.65 CNY, slightly better than -92,866,156.47 CNY in the previous period[51] - The company reported a net increase in cash and cash equivalents of 13,605,325.55 CNY, compared to 4,721,455.37 CNY in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,050,592,097.70, a 5.34% increase from CNY 3,845,271,645.91 at the end of the previous year[7] - Current liabilities rose to CNY 1,432,200,402.76, compared to CNY 1,393,193,723.61, indicating an increase of about 2.8%[36] - Long-term borrowings increased significantly to CNY 246,000,000.00 from CNY 146,000,000.00, marking a year-over-year increase of 68.5%[36] - The balance of accounts payable increased by 30 million yuan, a growth of 131.29%, mainly due to an increase in bank acceptance bills issued by the subsidiary Lihua Pharmaceutical[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,666[12] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 34.82% of the shares, totaling 141,615,094 shares[12] - Net assets attributable to shareholders reached CNY 1,950,186,198.67, showing a slight increase of 0.60% from CNY 1,938,648,669.32[7] Investments and Projects - The total amount of funds raised was 726.51 million yuan, with 36.47 million yuan invested in the current quarter[25] - The total investment commitment for the enzyme preparation project in Inner Mongolia is 9,500 million, with a completion progress of 99.80% as of June 30, 2018[26] - The marketing service network construction project has a total investment of 2,500 million, with a completion progress of 74.80% as of December 31, 2018[26] - The new steroid hormone GMP construction project has a total investment of 40,000 million, with a completion progress of 78.49% as of December 31, 2018[26] Operational Performance - Total operating costs for Q1 2018 were CNY 313,478,575.54, up from CNY 293,029,716.71 in the previous year, reflecting a year-over-year increase of 7%[42] - The company's operating revenue for Q1 2018 was CNY 85,475,243.31, an increase of 36.29% compared to CNY 62,762,396.66 in the same period last year[46] - The company's financial expenses increased to CNY 6,940,475.89 in Q1 2018, up from CNY 3,859,793.32 in Q1 2017[46] Risks and Challenges - The company faced risks related to business integration and increasing financial expenses due to external financing[10] - The marketing service network construction project has not been completed due to delays in overseas product registration processes[28]